HFS
GSK icon

Hantz Financial Services’s GSK GSK Stock Holding History

Hantz Financial Services’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.37M Sell
159,568
-1,463
-0.9% -$77.4K 0.11% 112
2026
Q1 		$8.89M Buy
161,031
+10,073
+7% +$546K 0.14% 103
2025
Q4 		$7.4M Buy
150,958
+18,904
+14% +$882K 0.11% 138
2025
Q3 		$5.7M Buy
132,054
+22,393
+20% +$875K 0.09% 193
2025
Q2 		$4.21M Buy
109,661
+7,515
+7% +$287K 0.07% 229
2025
Q1 		$3.96M Buy
102,146
+14,730
+17% +$539K 0.07% 233
2024
Q4 		$2.96M Buy
87,416
+7,858
+10% +$283K 0.05% 278
2024
Q3 		$3.25M Buy
79,558
+813
+1% +$33.3K 0.06% 266
2024
Q2 		$3.03M Sell
78,745
-2,746
-3% -$116K 0.06% 266
2024
Q1 		$3.49M Buy
81,491
+463
+0.6% +$19.1K 0.07% 261
2023
Q4 		$3M Sell
81,028
-927
-1% -$33.3K 0.07% 281
2023
Q3 		$2.97M Buy
81,955
+5,021
+7% +$178K 0.08% 258
2023
Q2 		$2.74M Buy
76,934
+2,348
+3% +$84.2K 0.07% 274
2023
Q1 		$2.65M Buy
74,586
+3,340
+5% +$117K 0.07% 265
2022
Q4 		$2.5M Buy
71,246
+4,869
+7% +$162K 0.08% 262
2022
Q3 		$1.95M Buy
66,377
+1,428
+2% +$54.1K 0.07% 274
2022
Q2 		$3.53M Buy
64,949
+2,810
+5% +$155K 0.12% 203
2022
Q1 		$3.38M Buy
62,139
+7,345
+13% +$399K 0.1% 222
2021
Q4 		$3.02M Buy
54,794
+6,135
+13% +$319K 0.09% 225
2021
Q3 		$2.32M Buy
48,659
+9,234
+23% +$464K 0.08% 231
2021
Q2 		$1.96M Buy
39,425
+12,076
+44% +$580K 0.07% 240
2021
Q1 		$1.22M Buy
27,349
+6,385
+30% +$290K 0.05% 270
2020
Q4 		$964K Sell
20,964
-5,508
-21% -$253K 0.04% 285
2020
Q3 		$1.25M Sell
26,472
-1,202
-4% -$60.2K 0.06% 238
2020
Q2 		$1.41M Sell
27,674
-760
-3% -$39K 0.08% 226
2020
Q1 		$1.35M Buy
+28,434
New +$1.52M 0.09% 211

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Hantz Financial Services's GSK Position: Q2 2026 in Review

Hantz Financial Services reduced its GSK (GSK) stake by 0.91% in Q2 2026, selling an estimated $77.4K and leaving 159,568 shares worth $8.37M. The position accounts for 0.11% of the portfolio, ranked #112.

Hantz Financial Services first reported a position in GSK in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.89M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Hantz Financial Services held 159,568 shares of GSK worth $8.37M as of Q2 2026.
  • Hantz Financial Services sold 1,463 GSK shares in Q2 2026, an estimated $77.4K.
  • GSK made up 0.11% of Hantz Financial Services's portfolio in Q2 2026, its #112 holding.
  • Hantz Financial Services first reported a position in GSK in Q1 2020 and has held it in 26 quarters since.
  • Hantz Financial Services's GSK position peaked at $8.89M in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.